These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23578955)

  • 1. MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma.
    Bourdeaut F; Grison C; Maurage CA; Laquerriere A; Vasiljevic A; Delisle MB; Michalak S; Figarella-Branger D; Doz F; Richer W; Pierron G; Miquel C; Delattre O; Couturier J
    Cancer Genet; 2013 Apr; 206(4):124-9. PubMed ID: 23578955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
    Pfister S; Remke M; Benner A; Mendrzyk F; Toedt G; Felsberg J; Wittmann A; Devens F; Gerber NU; Joos S; Kulozik A; Reifenberger G; Rutkowski S; Wiestler OD; Radlwimmer B; Scheurlen W; Lichter P; Korshunov A
    J Clin Oncol; 2009 Apr; 27(10):1627-36. PubMed ID: 19255330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-level copy number changes of MYC genes have a prognostic impact in medulloblastoma.
    Zitterbart K; Filkova H; Tomasikova L; Necesalova E; Zambo I; Kantorova D; Slamova I; Vranova V; Zezulkova D; Pesakova M; Pavelka Z; Veselska R; Kuglik P; Sterba J
    J Neurooncol; 2011 Mar; 102(1):25-33. PubMed ID: 20607354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Episomal amplification of MYCN in a case of medulloblastoma.
    Surace C; Pedeutour F; Trombetta D; Burel-Vandenbos F; Rocchi M; Storlazzi CT
    Virchows Arch; 2008 May; 452(5):491-7. PubMed ID: 18286303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of medulloblastoma in children under age of three years.
    Ryzhova MV; Zheludkova OG; Kumirova ÉV; Shishkina LV; Panina TN; Gorelyshev SK; Khukhlaeva EA; Mazerkina NA; Matuev KB; Medvedeva OA; Tarasova EM; Kholodov BV; Kapitul'skaia OIu
    Zh Vopr Neirokhir Im N N Burdenko; 2013; 77(1):3-10; discussion 11. PubMed ID: 23659115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.
    Korshunov A; Remke M; Werft W; Benner A; Ryzhova M; Witt H; Sturm D; Wittmann A; Schöttler A; Felsberg J; Reifenberger G; Rutkowski S; Scheurlen W; Kulozik AE; von Deimling A; Lichter P; Pfister SM
    J Clin Oncol; 2010 Jun; 28(18):3054-60. PubMed ID: 20479417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case report of a pediatric medulloblastoma with concurrent MYC and MYCN subclonal amplification in distinct populations of neoplastic cells.
    Minasi S; Gianno F; Bargiacchi L; Barresi V; Miele E; Antonelli M; Buttarelli FR
    Virchows Arch; 2024 Jul; 485(1):153-158. PubMed ID: 37212894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.
    Pfaff E; Remke M; Sturm D; Benner A; Witt H; Milde T; von Bueren AO; Wittmann A; Schöttler A; Jorch N; Graf N; Kulozik AE; Witt O; Scheurlen W; von Deimling A; Rutkowski S; Taylor MD; Tabori U; Lichter P; Korshunov A; Pfister SM
    J Clin Oncol; 2010 Dec; 28(35):5188-96. PubMed ID: 21060032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
    Korshunov A; Remke M; Kool M; Hielscher T; Northcott PA; Williamson D; Pfaff E; Witt H; Jones DT; Ryzhova M; Cho YJ; Wittmann A; Benner A; Weiss WA; von Deimling A; Scheurlen W; Kulozik AE; Clifford SC; Peter Collins V; Westermann F; Taylor MD; Lichter P; Pfister SM
    Acta Neuropathol; 2012 Apr; 123(4):515-27. PubMed ID: 22160402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fast detection of MYCN copy number alterations in brain neuronal tumors by real-time PCR.
    Malakho SG; Korshunov A; Stroganova AM; Poltaraus AB
    J Clin Lab Anal; 2008; 22(2):123-30. PubMed ID: 18348317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group.
    Aldosari N; Bigner SH; Burger PC; Becker L; Kepner JL; Friedman HS; McLendon RE
    Arch Pathol Lab Med; 2002 May; 126(5):540-4. PubMed ID: 11958658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of MYCN gene amplification in neuroblastoma using chromogenic in situ hybridization (CISH): an alternative and practical method.
    Bhargava R; Oppenheimer O; Gerald W; Jhanwar SC; Chen B
    Diagn Mol Pathol; 2005 Jun; 14(2):72-6. PubMed ID: 15905689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated cytogenetic and high-resolution array CGH analysis of genomic alterations associated with MYCN amplification.
    Pandita A; Bayani J; Paderova J; Marrano P; Graham C; Barrett M; Prasad M; Zielenska M; Squire JA
    Cytogenet Genome Res; 2011; 134(1):27-39. PubMed ID: 21508638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization.
    Tong CY; Hui AB; Yin XL; Pang JC; Zhu XL; Poon WS; Ng HK
    J Neurosurg; 2004 Feb; 100(2 Suppl Pediatrics):187-93. PubMed ID: 14758948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogene amplification in medulloblastoma: analysis of a case by comparative genomic hybridization and fluorescence in situ hybridization.
    Jay V; Squire J; Bayani J; Alkhani AM; Rutka JT; Zielenska M
    Pathology; 1999 Nov; 31(4):337-44. PubMed ID: 10643003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accumulation of genomic aberrations during clinical progression of medulloblastoma.
    Korshunov A; Benner A; Remke M; Lichter P; von Deimling A; Pfister S
    Acta Neuropathol; 2008 Oct; 116(4):383-90. PubMed ID: 18704466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients.
    Lamont JM; McManamy CS; Pearson AD; Clifford SC; Ellison DW
    Clin Cancer Res; 2004 Aug; 10(16):5482-93. PubMed ID: 15328187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma.
    Ryan SL; Schwalbe EC; Cole M; Lu Y; Lusher ME; Megahed H; O'Toole K; Nicholson SL; Bognar L; Garami M; Hauser P; Korshunov A; Pfister SM; Williamson D; Taylor RE; Ellison DW; Bailey S; Clifford SC
    Acta Neuropathol; 2012 Apr; 123(4):501-13. PubMed ID: 22139329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Array comparative genomic hybridization reveals unbalanced gain of the MYCN region in Wilms tumors.
    Schaub R; Burger A; Bausch D; Niggli FK; Schäfer BW; Betts DR
    Cancer Genet Cytogenet; 2007 Jan; 172(1):61-5. PubMed ID: 17175381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of a simplified comparative genomic hybridization technique to screen for gene amplification in pediatric solid tumors.
    Bayani J; Thorner P; Zielenska M; Pandita A; Beatty B; Squire JA
    Pediatr Pathol Lab Med; 1995; 15(6):831-44. PubMed ID: 8705194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.